Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
47
LCTX Quote, Financials, Valuation and Earnings
Last price:
$1.66
Seasonality move
:
11.05%
Day range:
$1.63 - $1.72
52-week range:
$0.37 - $2.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
34.67x
P/B ratio:
17.35x
Volume:
1.8M
Avg. volume:
1.9M
1-year change:
202.64%
Market cap:
$382.3M
Revenue:
$9.5M
EPS (TTM):
-$0.30
Analysts' Opinion
-
Consensus RatingLineage Cell Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.17, Lineage Cell Therapeutics, Inc. has an estimated upside of 151% from its current price of $1.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.66.
Fair Value
-
According to the consensus of 6 analysts, Lineage Cell Therapeutics, Inc. has 151% upside to fair value with a price target of $4.17 per share.
LCTX vs. S&P 500
-
Over the past 5 trading days, Lineage Cell Therapeutics, Inc. has underperformed the S&P 500 by -9.58% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lineage Cell Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lineage Cell Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Lineage Cell Therapeutics, Inc. reported revenues of $3.7M.
Earnings Growth
-
Lineage Cell Therapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Lineage Cell Therapeutics, Inc. reported earnings per share of -$0.13.
Enterprise value:
343.2M
EV / Invested capital:
14.66x
Price / LTM sales:
34.67x
EV / EBIT:
--
EV / Revenue:
31.73x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-16.44x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.9M
Return On Assets:
-67.24%
Net Income Margin (TTM):
-624.16%
Return On Equity:
-117.46%
Return On Invested Capital:
-112.65%
Operating Margin:
-102.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $8.8M | $8.7M | $10.8M | $3.8M | $3.7M | |
| Gross Profit | $7.6M | $7.7M | $9.9M | $3.6M | $3.5M | |
| Operating Income | -$25M | -$22.7M | -$20.3M | -$3.8M | -$3.8M | |
| EBITDA | -$24.3M | -$22.1M | -$19.7M | -$3.7M | -$3.6M | |
| Diluted EPS | -$0.13 | -$0.11 | -$0.30 | -$0.02 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $68.3M | $68.5M | $43.5M | $34.4M | $42.3M | |
| Total Assets | $131.2M | $131.1M | $106.2M | $96.6M | $89.6M | |
| Current Liabilities | $8.8M | $22.7M | $15.9M | $13.9M | $9.4M | |
| Total Liabilities | $11.6M | $53.6M | $39.5M | $31.8M | $68.8M | |
| Total Equity | $119.6M | $77.6M | $66.7M | $64.8M | $20.8M | |
| Total Debt | $2.7M | $2.3M | $2.2M | $1.7M | $1.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.9M | -$22.8M | -$20.4M | -$5.8M | -$3.6M | |
| Cash From Investing | $31.6M | $4.8M | $4.5M | $3.9M | -$12K | |
| Cash From Financing | $6.6M | $14.1M | $28.3M | -$3K | $1.8M | |
| Free Cash Flow | -$31.4M | -$23.1M | -$20.9M | -$5.9M | -$3.6M | |
LCTX
Sector
Market Cap
$382.3M
$28.4M
Price % of 52-Week High
79.43%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-7.27%
-1.49%
1-Year Price Total Return
202.64%
-16.67%
Beta (5-Year)
1.776
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.72
200-day SMA
Buy
Level
$1.11
Bollinger Bands (100)
Buy
Level
1.28 - 1.82
Chaikin Money Flow
Buy
Level
6.6M
20-day SMA
Sell
Level
$1.71
Relative Strength Index (RSI14)
Sell
Level
45.25
ADX Line
Sell
Level
7.88
Williams %R
Neutral
Level
-80
50-day SMA
Sell
Level
$1.74
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
19.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.3033)
Sell
CA Score
(Annual)
Level (-0.5917)
Buy
Beneish M-Score
(Annual)
Level (-2.3824)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.4165)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Stock Forecast FAQ
In the current month, LCTX has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LCTX average analyst price target in the past 3 months is $4.17.
-
Where Will Lineage Cell Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lineage Cell Therapeutics, Inc. share price will rise to $4.17 per share over the next 12 months.
-
What Do Analysts Say About Lineage Cell Therapeutics, Inc.?
Analysts are divided on their view about Lineage Cell Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lineage Cell Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Lineage Cell Therapeutics, Inc.'s Price Target?
The price target for Lineage Cell Therapeutics, Inc. over the next 1-year time period is forecast to be $4.17 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LCTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lineage Cell Therapeutics, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LCTX?
You can purchase shares of Lineage Cell Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lineage Cell Therapeutics, Inc. shares.
-
What Is The Lineage Cell Therapeutics, Inc. Share Price Today?
Lineage Cell Therapeutics, Inc. was last trading at $1.66 per share. This represents the most recent stock quote for Lineage Cell Therapeutics, Inc.. Yesterday, Lineage Cell Therapeutics, Inc. closed at $1.66 per share.
-
How To Buy Lineage Cell Therapeutics, Inc. Stock Online?
In order to purchase Lineage Cell Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get LCTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LCTX
Sector
P/E ratio
--
23.89x
PEG ratio
-0.03x
-0.01x
P/B ratio
17.35x
1.81x
Price / LTM sales
34.67x
1.58x
Growth Metrics
LCTX
Sector
Revenue growth
-2.59%
4.62%
Earnings growth
-708.08%
10.7%
Revenue (5-year growth)
45.08%
6.5%
Earnings forecast
-$0.03
-$0.21
Profitability
LCTX
Sector
Profitability FY 2024
$8.6M
$3.6M
Return on invested capital
-112.65%
-31.84%
Return on assets
-67.24%
-27.96%
Return on equity
-117.46%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
9
Estimated Next Earnings Date
Feb
5
Balance Sheet
LCTX
Sector
Total cash
$40.5M
$26.4M
Short term investments
$2M
$25.7M
Total assets
$113.2M
$76.9M
Long term debt
$1.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 24
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
